Important Updates from Pharmacy Services

Chris Mitsuoka | PHARMACY SERVICES

Exubera Off the Market: Regrettably, Pfizer has chosen to discontinue marketing their new inhaled form of Insulin (Exubera). Over the past year, sales have not justified the continued marketing of the medication.

A continued area of concern for the clinics
is the handling of multi-dose injectable vials.

Tracking Punctured Vials: It is very important that every multi-dose vial be clearly marked with the date that the vial was initially punctured. All multi-dose vials, except for State provided vaccines, must be discarded 30 days from the date indicated on the punctured vial.

Dilantin Has a New Look: There has been a change in the appearance of brand Dilantin 100mg Kapeals. The former Kapseal (White with an orange band) has been replaced by a standard half white and half orange capsule. If your patients call to ask if this is still the correct medication, you may assure them that it is still the brand-name Dilantin, just in a different-looking capsule. The new capsules meet the federal requirements for bioequivalence. For the time being, no changes have been made to the 30mg Dilantin Kapseal.

Close The Loop With Patients: The pharmacy delivery system continues to grow to service patients in outlying CHC clinics. Feedback is that patients appreciate the service and cooperation from the clinic staff. To close the loop, please be sure to collect the co-payment for the prescription and complete the deposit documentation.

If there are any questions regarding collection of the co-payments, please contact Steve Festor in the pharmacy (sfestor@chccc.org).